314 related articles for article (PubMed ID: 8330870)
1. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
[TBL] [Abstract][Full Text] [Related]
2. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
3. [Bronchial carcinoid tumor and scintigraphy of somatostatin receptors: detection of bone metastasis].
Banzo J; Abós MD; Prats E; García F; Freile E; Razola P; Escalera T
Rev Esp Med Nucl; 2001 Oct; 20(6):431-8. PubMed ID: 11578577
[TBL] [Abstract][Full Text] [Related]
4. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution of 111In-pentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden.
Adrian HJ; Dörr U; Bach D; Bihl H
Horm Metab Res Suppl; 1993; 27():18-23. PubMed ID: 8330868
[TBL] [Abstract][Full Text] [Related]
6. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
7. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.
Lebtahi R; Cadiot G; Delahaye N; Genin R; Daou D; Peker MC; Chosidow D; Faraggi M; Mignon M; Le Guludec D
J Nucl Med; 1999 Oct; 40(10):1602-8. PubMed ID: 10520698
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
10. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
11. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
Bernhardt P; Ahlman H; Nilsson O; Benjegård SA; Forssell-Aronsson E
Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
[No Abstract] [Full Text] [Related]
12. [Isotopic scan with somatostatin receptors in a case of recurrent carcinoid tumor. Relevance of tomographic detection].
Bernà Roqueta L; Martín Marimón JC; Martín Martínez J
Rev Esp Med Nucl; 2002 Apr; 21(2):123-4. PubMed ID: 11879622
[No Abstract] [Full Text] [Related]
13. Metastatic carcinoid tumor imaged with CT and a radiolabeled somatostatin analog: a case report.
Lobrano MB; McCarthy K; Adams L; Neitzschman H
Am J Gastroenterol; 1997 Mar; 92(3):513-5. PubMed ID: 9068482
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
15. Changes in the expression of somatostatin receptor imaging following Y-90 lanreotide therapy for carcinoid tumor: a flare response?
Popadic S; Al-Nahhas A; Naili Q; Todd J; Meeran K
Clin Nucl Med; 2005 Apr; 30(4):238-40. PubMed ID: 15764878
[TBL] [Abstract][Full Text] [Related]
16. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
17. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
Seifert JK; Görges R; Bockisch A; Junginger T
Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
[TBL] [Abstract][Full Text] [Related]
19. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
20. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
